Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

manilatimes.net · 2026-08-07

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the 'Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the 'Committee”) without stockholder approval.

TickrTrends take: Pacira BioSciences' inducement grants under Nasdaq rules represent standard equity compensation for new executives, a practice common across the technology sector that can dilute shareholder value over time. Given TickrTrends' current assessment that PLXS trades at overvalued levels, investors focused on valuation metrics should monitor whether such equity grants increase the company's share count materially enough to further pressure per-share earnings. The combination of potentially elevated valuation multiples alongside ongoing equity dilution from inducement grants creates a dynamic that valuation-conscious shareholders typically track closely.

Read the full story at manilatimes.net →